Evidence map›Paper›PMID 42138182›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Remote, unsupervised assessment of cognitive impairment and decline in Alzheimer's disease using the Cogstate Brief Battery in ADNI-3.

Paul Maruff, Bruce Albala, Danielle Harvey, Naomi Saito, Shaveta Kanoria, Paul Aisen, Ronald Petersen, Michael W Weiner, Laurel Beckett, Alzheimer's Disease Neuroimaging Initiative

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Paul MaruffCogstate Ltd, Melbourne, Australia.
Bruce AlbalaDepartment of Environmental & Occupational Health, Wen School of Population and Public Health, University of California, Irvine, California, USA.
Danielle HarveyDepartment of Public Health Sciences, University of California, Davis, California, USA.
Naomi SaitoDepartment of Public Health Sciences, University of California, Davis, California, USA.
Shaveta KanoriaDepartments of Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology, University of California, San Francisco, San Francisco, California, USA.
Paul AisenAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Ronald PetersenDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Michael W WeinerDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Laurel BeckettDepartment of Public Health Sciences, University of California, Davis, California, USA.
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MONICA G. RIVERA-MINDT · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
CIHRFoundation for the National Institutes of HealthNIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904NIBIB NIH HHSNIH HHS U01AG024904NIH HHS U19 AG024904Northern California Institute for Research and Education
6 · The paper itself

Abstract

introductionRemote neuropsychological testing can monitor brain health in individuals with or at risk of Alzheimer's disease (AD). We evaluated acceptability and validity of the Cogstate Brief Battery (CBB) for remote administration.

methodsNon-demented adults from the Alzheimer's Disease Neuroimaging Initiative (ADNI) completed the CBB in-clinic under supervision, then remotely every six months, with annual in-clinic reassessments. Groups included cognitively unimpaired (CU) adults with normal amyloid (CU Aβ-) or elevated amyloid (CU Aβ+), and individuals with mild cognitive impairment with or without amyloid (MCI Aβ+, MCI Aβ-). Performance was compared across contexts and longitudinal changes were examined.

resultsAt baseline, MCI Aβ+ participants performed worse than CU Aβ-. CBB performance was similar across contexts, with consistent group differences. Over time, MCI Aβ+ participants showed greater decline on remote CBB measures than CU Aβ- adults. DISCUSSION: Remote unsupervised CBB assessments are valid, reliable, and sensitive to AD-related cognitive impairment.

Indexed as

Alzheimer DiseaseCognitive DysfunctionNeuropsychological TestsAgedAged, 80 and overAmyloid beta-PeptidesDisease ProgressionFemaleHumansLongitudinal StudiesMaleReproducibility of ResultsAmyloid beta-PeptidesAlzheimer's disease (AD)cognitionCogstate Brief Batterycomputerized neuropsychological testingmild cognitive impairment (MCI)

Identifiers

PMID42138182
PMCPMC13177345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.